Rami El-Yousef, MD
Pulmonary Disease · Newhall, CANPI 1861750846
Payments from drug & device makers
What this record shows
This record is dominated by education: $7,500 of the $10,890 with a category attached, or 68.9%. Intuitive Surgical accounts for 71.4% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2024 at $5,834 and has fallen 88.9% since, to $648 in 2025.
Across 109 payments — averaging $99.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$8K
- Sanofi$600
- GSK$597
- Boehringer Ingelheim$426
- AstraZeneca$300
- Regeneron Healthcare Solutions, Inc.$214
- plus $980 from 18 others
Across 7 payments — averaging $14,063 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$65K
- Astrazeneca UK Limited$18K
- GSK$16K
What the payments were for
- Travel & lodging$1401%
- Food & beverage$3,24930%
- Education$7,50069%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 7 | $7,773 |
| Sanofi | 25 | $600 |
| GSK | 16 | $597 |
| Boehringer Ingelheim | 12 | $426 |
| AstraZeneca | 8 | $300 |
| Regeneron Healthcare Solutions, Inc. | 7 | $214 |
| Abiomed | 2 | $165 |
| Insmed, Inc. | 4 | $133 |
| Philips North America LLC | 3 | $92 |
| Amgen | 5 | $88 |
| Mylan Specialty L.p. | 3 | $71 |
| Inspire Medical Systems, Inc. | 2 | $63 |
| Grifols USA, LLC | 3 | $57 |
| Advanced Respiratory, Inc | 2 | $43 |
| Lilly USA, LLC | 1 | $34 |
| Pfizer | 1 | $34 |
| Pulmonx Corporation | 1 | $29 |
| Genentech USA, Inc. | 1 | $29 |
| United Therapeutics Corporation | 1 | $28 |
| Merck | 1 | $27 |
| Baxter Healthcare | 1 | $25 |
| Electromed, Inc. | 1 | $22 |
| ERBE USA Inc | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$4,634
- ION$3,000
- AREXVY$250
- OFEV$125
- ANDEXXA$125
How this compares
$10,890 in reported general payments places this provider in the 80th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 32 | $375,967 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 318 | $247,941 |
| NucalaMepolizumab | 29 | $117,550 |
| Dupixent PenDupilumab | 15 | $85,087 |
| Breo ElliptaFluticasone/Vilanterol | 134 | $59,839 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 63 | $53,254 |
| Dupixent SyringeDupilumab | 11 | $41,417 |
| EliquisApixaban | 25 | $26,273 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 55 | $25,817 |
| Spiriva RespimatTiotropium Bromide | 28 | $19,415 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 32 | $17,881 |
| SymbicortBudesonide/Formoterol Fumarate | 31 | $9,822 |
| XareltoRivaroxaban | 15 | $6,016 |
| Pulmicort FlexhalerBudesonide | 18 | $5,711 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 235 | $5,389 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta | $597 | $451,146536 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $426 | $413,26392 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler | $300 | $68,786112 claims |
| PfizerEliquis | $34 | $26,27325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Newhall
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
- David PhamWestminster$571K
- Vijay BalasubramanianFresno$529K
- Victor TapsonLos Angeles$514K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.